Dear CUA member,
On November 21, 2016, Sanofi Pasteur publicly announced that production of ImmuCyst BCG will cease at the manufacturing facility in Canada in mid-2017.  However, they expect to continue to supply doses to Canada until the end of 2018.  Their website post indicates that this decision is not linked to any safety issues and that all of the doses of BCG which have been released meet all quality, safety and efficacy requirements.
View the post on Sanofi Pasteur’s website http://www.sanofipasteur.ca/node/50701 
Although the majority of the current Canadian BCG market is using Tice BCG produced by Merck, Bladder Cancer Canada is concerned about the potential impact of having only one BCG supplier in Canada in the near future.  They will be taking steps in the coming weeks and months to address patient needs and concerns.  
Sincerely,
Wassim Kassouf, MD, CM, FRCSC
Chair, BCC Medical Advisory Board
Pour lire ce message en français, s'il-vous-plaît suivez le lien
https://bladdercancercanada.org/fr/news/sanofi-pasteur-cessera-de-produire-limmucyst-bcg/